Showing posts with label sterility. Show all posts
Showing posts with label sterility. Show all posts

Thursday, November 1, 2018

myLotus becomes the first and only quantitative fertility tracking home test to get clearance in Europe


Concepta Plc, a company based in Bedfordshire, UK, announced the approval of its breakthrough product, myLotus® in Europe. myLotus assists women to conceive naturally by quantitatively measuring the LH surge to pinpoint the day of ovulation. 

myLotus is scheduled to be launched this weekend at The Fertility Show in Olympia, London on November 3-4. The system consists of myLotus fertility monitor, ovulation test strips and pregnancy test strips and myLotus fertility App.

The woman must dip the ovulation strip into the urine sample and insert it into the fertility monitor. The monitor provides a “+” and “–” fertility test result and measures the levels of Luteinising Hormone (LH) present in your urine. This quantitative estimation of LH  makes it different from traditional (qualitative) ovulation tests. Women can continue to test throughout the menstrual cycle to know about the pattern of LH levels and surge.

The pregnancy test provided allows for easy testing for conception in the days following LH surge results.

The LH test results can be entered in the App and viewed in graphic form to know more about the fertile time for intimacy. The results are as accurate as the laboratory-based test without the hassle of leaving your home. Data can be shared with your healthcare provider to improve your chance of conception.

Matthew Walls, Chairman said: "The Fertility Show marks the UK launch of our myLotus® fertility product and the start of our roll-out across CE territories. Women attending the show can exclusively buy a Starter Pack, consisting of a myLotus® monitor, three packs of 20 Ovulation Tests (LH) and three packs of 3 Pregnancy Tests (hCG), at the 'Special Launch' price of £199. We look forward to an exciting Fertility Show and to welcoming women and couples to our stand.
Here is a simple animation video to know more about myLotus


Here is a video to know about how the fertility monitor works




Thursday, October 11, 2018

News from ASRM 2018: Some interesting research papers on male factor infertility


The American Society of Reproductive Medicine just wrapped up its 2018 scientific congress and expo at Denver, Colorado.  Here are some of the research highlights presented at the society about male factor infertility. 

A diagnosis of azoospermia puts men at increased risk of death


Results of a large prospective cohort study report a link between azoospermia and increase the risk of mortality. The study findings were jointly presented by Scandinavian and American researchers at the meeting. Interestingly, the increased risk of dying was not observed for men with oligospermia. 

The authors analyzed data of 51,289 men from the Danish National IVF register from 2006 through 2016 and followed those with azoospermia till the end of study period, death or till they emigrated from Denmark. Vasectomized men and men with normal semen parameters were used as a reference.
The average follow-up period was eight years. Men with azoospermia faced twice the increased risk of dying as compared to men with oligospermia and normal semen parameters.  The mean age at death was 48.8, and the most common cause of death was CVD and cancer.  

Another previous cohort study from Denmark also documented that as the percentages of motile and morphologically normal spermatozoa and semen volume increased, mortality decreased in a dose-response manner (P(trend) < 0.05).

Peter Schlegel, MD, ASRM President-Elect, noted, “A man’s infertility status is a component of his whole health status. Semen analysis results exist on a continuum, but a diagnosis of azoospermia may be a call to take a closer look at a man’s overall health in addition to his reproductive function.”
Thus, Semen parameters could be a key biomarker of overall male health.


Inadequate sleep is linked to Low Testosterone Levels in Men

Lack of sleep is associated with decreasing testosterone levels in US male reports the results of a study presented at the ASRM scientific congress at Denver, Colorado. The other culprits for low testosterone were aging, increasing BMI and alcohol consumption.

The researchers examined the data on nearly 2300 males, aged 16-80 years from The National Health and Nutrition Examination Survey (NHANES). The subjects reported an average sleep duration of 6.86 hours (2-12 hours) and had average serum testosterone levels of 303.33 ng/dL (43.39 ng/dL to 779.2 ng/dL).

After accounting for confounders, the researchers noted that serum testosterone levels decreased by 0.49 ng/dL per year of age, 5.85 ng/dL per lost hour of sleep, 6.18 ng/dL per BMI unit increase, and 2.99 ng/dL per each unit increase in alcohol consumption.

Robert Brannigan, MD, a member of ASRM’s Board of Directors, remarked “Reduction in testosterone level can have deleterious effects on a man’s health beyond his fertility and sexual function.  Testosterone is essential for good metabolic function and decreased levels of the hormone are associated with metabolic syndrome and cardiovascular disease.  Low testosterone can contribute to fatigue and depression, as well. A balanced diet and a healthy sleep routine are interventions a man can take on his own to help keep his T levels stable.”


A decline in sperm count and motility observed in North America and Europe

Two studies presented at the ASRM scientific congress showed that semen quality has seen a decline in patients undergoing fertility treatment and donors in this century. In the first study, researchers from one European and the other North American center evaluated the results of semen analysis from 119,972 men seeking infertility treatment between 2002 through 2017.

The researchers looked at the most reliable indicator of male fertility, the total motile sperm count (TMSC) and grouped the study population into 3 groups: TMSC greater than 15 million; TMSC 5 to 15 million: and TMSC zero to 15 million.

The percentage of patients in Group 1 (highest TMSC) declined from 84.7% in the time period 2002-2005 to 79.1% in 2014-2017, while the percentage in Group 3 (lowest TMSC) rose from 8.9% to 11.6% over those time periods.

TMSC decreased by 1.1% per year as the men aged and thus patients who belonged to Group 1 were slowly slipped into Group 2 as they age.   

For the second study researchers from the Ichan School of Medicine at Mount Sinai, California Cryobank, and Reproductive Medical Associates of New York observed a progressive decline in semen quality in donors over 11 years in six cities:  Los Angeles, Palo Alto, Houston, Boston, Indianapolis, and New York City.

Over a period of 10 years, the researchers analyzed 124,107 semen specimens provided by 2586 donors aged 19 to 38. They looked at three semen parameters- total count, average concentration, and TMSC-  as a whole and region by region.

A decrease in all three parameters was observed in all regions, except New York. ASRM President-elect Peter Schlegel, MD, said, “The trend toward lower sperm counts in this study is concerning.  Whether the causes underlying it are environmental or lifestyle-related, they will be difficult to parse out.  Pollution, endocrine disrupting chemicals, poor exercise habits and convenient, yet nutritionally poor, dietary choices could all play a part.  Similarly, men may now be referred for advanced medical care despite having lower sperm numbers, reflecting our improved reproductive treatments.  Men planning to conceive should do what they can to achieve their best overall health to optimize their sperm quality.”